| Date | Title | Description |
| 25.05.2023 | Strong long-term results with CERAMENT®G for severe open fractures – study from Manchester University Hospital | Published: 2023-05-25
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep i... |
| 23.05.2023 | Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala | Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, accepted the Corporate Partner Award
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–May 22, 2023– Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focuse... |
| 23.05.2023 | Vicore obtains significant new patent protection for C21 in the US | Stockholm, May 23, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”) today announces issuance of a new US patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase... |
| 19.05.2023 | Vicore reports new 36-week data from the AIR trial demonstrating sustained disease stabilization and increase in lung function in IPF patients | Stockholm, May 19, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, today announces an updated interim analysis of its AIR phase 2a trial wi... |
| 17.05.2023 | Vicore to host webcast with updated AIR trial results after presentation at the ATS congress | Stockholm, May 17, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, will hold a webcast including a Q&A session to present interim r... |
| 16.05.2023 | Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations | DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targe... |
| 15.05.2023 | Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates | CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203
Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Top... |
| 12.05.2023 | Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results And Clinical Program Updates | FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update
Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
Clinical p... |
| 12.05.2023 | Oncopeptides presents new data at the European Haematology Association meeting | May 11, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that final efficacy and saf... |
| 12.05.2023 | Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights | Initiated a Phase 1 Sub-Study of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors
Expanded clinical manufacturing capacity through successful technology transfer of CT-0508
Closed mer... |
| 12.05.2023 | UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer | Berlin, Germany, and Brussels, Belgium, 11 May 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers,and UCB (EURONEXT BRUSS... |
| 11.05.2023 | 100% limb salvage rate in complex diabetic foot cases with CERAMENT® G/V – study from King’s College Hospital, London | Published: 2023-05-10
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the recent publication of clinical data demonstrating 100% limb salvage rate and 100% ulcer resolution with the c... |
| 11.05.2023 | HelloBetter received FDA Breakthrough Device Designation for Digital Therapeutic to treat Panic Disorder | Berlin, Germany, April 2023 – HelloBetter, one of the world’s leading providers in developing and commercializing software-based medicines called prescription digital therapeutics (PDTx), has received Breakthrough Device Designation from th... |
| 04.05.2023 | Oncopeptides publishes Q1 report 2023 | May 4, 2023
Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today publishes the report for t... |
| 04.05.2023 | Interim report January-March 2023 | 2023-05-04| REGULATORY
Stockholm, May 4, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the first quarter 2023.
... |
| 03.05.2023 | Pulmonx Reports First Quarter 2023 Financial Results | REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter... |
| 03.05.2023 | Vicore initiates clinical proof-of-concept study of endothelial dysfunction | Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces the first patient dosed with C21 in a clinical stu... |
| 03.05.2023 | Oncopeptides issues warrants to utilize the first loan tranche from EIB | May 3, 2023 Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat haematological diseases, today announced that the company... |
| 03.05.2023 | Fusion Pharmaceuticals Announces Opening Of Radiopharmaceutical Manufacturing Facility To Produce Targeted Alpha Therapies For Cancer | HAMILTON, ON, May 2, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the opening of its sta... |
| 02.05.2023 | Invitation to presentation of the Q1 report 2023 | May 2, 2023
Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quarter 2023 at 08:00 (CET) on M... |
| 27.04.2023 | BONESUPPORT HOLDING AB (publ) – Publishes Q1 2023 interim report | Published: 2023-04-27
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2023.
CONTINUED STRONG GROWTH
JANUARY – MARCH 2023
“S... |
| 25.04.2023 | Oncopeptides publishes the 2022 Annual Report | April 25, 2023
Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that the 2022... |
| 21.04.2023 | Fusion Pharmaceuticals Announces Presentation Of Preclinical Data Supporting FPI-2059 And Leading Targeted Alpha Therapy Platform At AACR Annual Meeting | FPI-2059 induces tumor growth inhibition in colorectal tumor model
TEM-1 and EGFRvIII demonstrate potential as TAT targets
HAMILTON, ON and BOSTON, April 19, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage... |
| 21.04.2023 | Oncopeptides presents new scientific data at European Myeloma Network Meeting | April 20, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company present... |
| 18.04.2023 | Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline | Berlin, Germany, 18 April 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces the successful completion o... |
| 17.04.2023 | Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting | PHILADELPHIA, PA – April 14, 2023 – Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced three abstracts were accepted for presentat... |
| 14.04.2023 | Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting | Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, will be presenting nove... |
| 14.04.2023 | Fusion Pharmaceuticals Announces IND Clearance For FPI-2068, A Jointly Developed Novel Targeted Alpha Therapy | FPI-2068 is a Bispecific Targeted Alpha Therapy (TAT) designed to Precisely Deliver Radiation to Tumor Cells
HAMILTON, ON and BOSTON, April 12, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology compa... |
| 05.04.2023 | Vicore Pharma publishes the Annual Report for 2022 | Stockholm, April 5, 2023 –Vicore Pharma Holding AB (publ) (“Vicore” or “company”) unlocking the potential of a new class of drugs – angiotensin II type 2-receptor agonists (ATRAGs), today announced the publication of the Annual Report for t... |
| 05.04.2023 | Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights | Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol “CARM”
Cash position as of the closing of the merger with Sesen Bio provides anticipated operating runway through 2024
PHILADELPHIA, April 4, 2023 /PRNewswir... |
| 04.04.2023 | Adcendo ApS Announces Extension of Series A financing to 82M EUR toEnsure Broad Development of its First-in-class ADC Pipeline | Copenhagen, Denmark, April 4th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the su... |
| 01.04.2023 | Vicore to announce AIR trial update at the ATS congress on May 21st | Stockholm, March 31, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces an oral presentation of updated interim data from th... |
| 01.04.2023 | Doctrin receives ISO/IEC 27001 certification | 2023-03-31
Doctrin is proud to announce that the company has received its ISO/IEC 27001:2013 certification. The certification marks an important milestone on Doctrin’s journey to continuously improve processes and risk management.
After a... |
| 01.04.2023 | Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations | DOYLESTOWN, Pa., March 30, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics tar... |
| 30.03.2023 | Vicore receives Innovation Passport designation by the UK regulatory agency MHRA for C21 in IPF | Stockholm, March 29, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2-receptor agonists (ATRAGs), today announces that the UK MHRA (Medicines and Healthcare products ... |
| 28.03.2023 | Oncopeptides receives a research grant from Sweden´s Innovation Agency to explore the PDC platform in solid tumors | March 28, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company has rece... |
| 22.03.2023 | Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1 Study Of FPI-2059, A Targeted Alpha Therapy (TAT) For The Treatment Of Solid Tumors Expressing NTSR1 | HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the... |
| 17.03.2023 | Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates | CAHmelia-203 in Adult Classic CAH Surpasses 50% Enrollment
Private Placement Financing of $53.6 million in Gross Proceeds with Top-Tier Healthcare Investors
Strategic Partnership and Exclusive Licensing Agreement with Kaken Pharmaceutical... |
| 16.03.2023 | Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results And Clinical Program Updates | Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC
FPI-1434 preliminary Phase 1 data expected in Q2 2023
FPI-1966 and FPI-2059... |
| 15.03.2023 | Targovax ASA: circRNA poster to be presented at the AACR Annual Meeting | Oslo, Norway, 15 March 2023 – Targovax ASA (OSE: TRVX) today announces that an abstract describing its circular RNA platform has been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meetin... |
| 14.03.2023 | Targovax: First patient dosed with TG01 in the USA | Oslo, Norway, 14 March 2023 – Targovax ASA (OSE: TRVX), today announces that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer... |
| 10.03.2023 | Oncopeptides CSO released from custody | March 10, 2023
Regulatory
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, has been informed that th... |
| 08.03.2023 | Targovax to prioritize resources on unlocking the potential of its circRNA platform | Oslo, Norway, 7 March 2023 Targovax ASA (OSE: TRVX) today announces that it will focus existing financial resources on developing its circular RNA (circRNA) platform to capitalize on its significant early-mover advantage and globally compet... |
| 08.03.2023 | Carisma Therapeutics Closes Merger with Sesen Bio | Shares of Carisma to commence trading on Nasdaq under new ticker symbol “CARM” on March 8, 2023
Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carism... |
| 08.03.2023 | Oncopeptides CSO investigated for violation of the Market Abuse Act | March 8, 2023
Regulatory
Oncopeptides AB (publ), has been informed by the Swedish Economic Crime Authority that the CSO Jakob Lindberg has been arrested for a suspected violation of the Market Abuse Act (Sw. lag om straff för marknadsmiss... |
| 03.03.2023 | Hemab Therapeutics’ Statement Announcing the Planned Departure of Co-Founder and CTO Johan Faber | COPENHAGEN, Demark and BOSTON, March 1, 2023
Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today issued the following s... |
| 03.03.2023 | Sesen Bio Stockholders Approve Merger with Carisma Therapeutics | Declares Special Dividend in the Aggregate of $75 Million
Approximately 88% Voted in Favor of the Merger at the Special Meeting
Merger on Track to Close on March 7, 2023
CAMBRIDGE, Mass. — March 2, 2023 — Sesen Bio, Inc. (Nasdaq: SESN) (... |
| 02.03.2023 | Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | DOYLESTOWN, Pa., March 01, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA dama... |
| 28.02.2023 | Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock | DOYLESTOWN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damag... |
| 28.02.2023 | Year-end report 2022 | Stockholm, February 28, 2023 – Vicore Pharma Holding AB (publ) publishes the year-end report for 2022.
Important events during the fourth quarter
Important events after the period
Financial overview for the period
October 1 – December 31... |
| 24.02.2023 | Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock | DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damag... |
| 24.02.2023 | Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results | REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quart... |
| 22.02.2023 | HealthCap Portfolio Company Hemab Therapeutics raises $135M Series B Financing | HealthCap VIII portfolio company Hemab Therapeutics today announced the closing of an oversubscribed $135 million Series B financing. The round was led by Access Biotechnology with participation from new investors Deep Track Capital, Avoro ... |
| 16.02.2023 | Oncopeptides publishes year-end report 2022 | February 16, 2023
Regulatory
Oncopeptides AB (publ), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2022.
Finan... |
| 16.02.2023 | Targovax ASA: Fourth quarter 2022 results | Oslo, Norway, 16 February 2023 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter 2022 results.
Members of Targovax’s exe... |
| 16.02.2023 | Targovax announces financing of up to NOK 300m over three years to advance its clinical cancer programs & pre-clinical circular RNA platform | Oslo, Norway, 16 February 2023 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target solid tumors, today announces that it has agreed the terms and conditions for a convertible bond faci... |
| 16.02.2023 | Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger | Amend Merger Agreement to Increase Expected Special Cash Dividend to $75 Million and Extend Contingent Value Right for Vicineum to March 31, 2027
Bradley L. Radoff and Michael Torok to Vote Shares in Support of Transaction
Michael Torok t... |
| 16.02.2023 | Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI) | DOYLESTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, t... |
| 16.02.2023 | BONESUPPORT HOLDING AB (publ) – publishes year-end report 2022 | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the fourth quarter 2022 and the full year 2022.
68 PERCENT SALES GROWTH IN THE QUARTER
OCTOBER –... |
| 15.02.2023 | Fusion Pharmaceuticals To Acquire Phase 2 Program For 225Ac-PSMA I&T, A Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer | Acquisition of Phase 2 program with established clinical proof of concept strengthens pipeline of innovative targeted alpha therapies
In connection with the transaction, Fusion announces $60.0 million private placement financing
Fusion to... |
| 14.02.2023 | Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split | DOYLESTOWN, Pa., Feb. 13, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (... |
| 10.02.2023 | Targovax ASA: Invitation to Targovax’s fourth quarter 2022 presentation, Thursday 16 February | Oslo, Norway, 8 February 2023 – Targovax ASA (OSE: TRVX) will announce its fourth quarter 2022 results on Thursday 16 February 2023. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, ana... |
| 10.02.2023 | Spruce Biosciences Announces $53.6 Million Private Placement Financing | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Feb. 9, 2023– Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significan... |
| 10.02.2023 | Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 | REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth ... |
| 10.02.2023 | Invitation to presentation of the year-end report 2022 | Oncopeptides AB (publ) a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, will publish the report for the fourth quarter and the 2022 year-end report, at ... |
| 09.02.2023 | Carisma Therapeutics Appoints Moderna CSO of External Research Ventures, Lin Guey, to Scientific Advisory Board | PHILADELPHIA, Feb. 7, 2023 /PRNewswire/ — Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced the appointment of Lin Guey, PhD to the company’s Sc... |
| 02.02.2023 | Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board | Expansion of Scientific Advisory Board provides additional expertise in development capabilities
PHILADELPHIA – January 31, 2023 – Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing ... |
| 02.02.2023 | Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer | Berlin, Germany, 1 February 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to a... |
| 31.01.2023 | Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
| DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, t... |
| 24.01.2023 | Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoi... | Dublin, Ireland – January 23, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod today announced that the first patients have been enrolled in the pivot... |
| 19.01.2023 | HelloBetter Sleep: First online therapy programme for organic and nonorganic insomnia available on prescription in Germany | Berlin, 20.12.2022 – HelloBetter Sleep has secured approval as HelloBetter’s sixth DiGA (prescription digital therapeutic) by the German Federal Institute for Drugs and Medical Devices (BfArM) and is now included in the DiGA directory. Hell... |
| 11.01.2023 | Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors | DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, t... |
| 11.01.2023 | Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia | Bispecific antibody HMB-001 positioned as the first prophylactic treatment for rare bleeding disorders
CEO Benny Sorensen, MD, PhD, delivered the update during a corporate overview presented at the 41st Annual JP Morgan Healthcare Conferen... |
| 11.01.2023 | Oncopeptides appoints Holger Lembrer as Chief Financial Officer | STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointe... |
| 09.01.2023 | Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 | Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) Anticipated in 2H 2023
Amendment to Phase 2 CAHptain Clinical Trial in Pediatric Classic CAH Enhances Study Design; Topline Data from Adolescents Antic... |
| 07.01.2023 | Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan | Partnership aims to accelerate global development and commercialization plans for tildacerfont to address worldwide unmet medical need in congenital adrenal hyperplasia (CAH)
Deal advances strategy to partner tildacerfont commercial rights... |
| 07.01.2023 | Fusion Pharmaceuticals And BWXT Medical Announce Actinium-225 Partnership To Scale Supply For Developing Targeted Alpha Therapies | – Agreement augments Fusion’s existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows
– Furthers BWXT Medical’s position as a global leader in medical isotope supply
HAMILTON, ON, Jan. 5, 2023 /PRNe... |
| 05.01.2023 | Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform | Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, today announces a license agreement with ... |
| 05.01.2023 | Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer | STOCKHOLM — January 4, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Board of Directors ha... |
| 03.01.2023 | Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger | Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
Sesen Bio Stockholders Expected to Receive Approximately $70 Million Special Cash Dividend,
an Increase fr... |
| 22.12.2022 | Targovax announces that the TG01 study in multiple myeloma at Oslo University Hospital has received regulatory approvals to proceed | Oslo, Norway, 22 December 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target solid tumors, today announces that the planned clinical trial with mutant RAS cancer vaccine TG01 in ... |
| 15.12.2022 | Marston Forest Healthcare live with Doctrin – the next generation care navigation and online consultation platform | Press release – 15 December 2022
Marston Forest Healthcare, a 10,000 patient GP practice in Berkshire have gone live with the Doctrin platform – a next generation care navigation and online consultation platform deployed to over 360 custom... |
| 15.12.2022 | American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema | Pulmonx Highlights 2022 Partnership with Lung Association
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Dec. 14, 2022– Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, has par... |
| 15.12.2022 | Targovax announces clinical trial collaboration with Agenus to test TG mutant RAS vaccination in pancreatic cancer | Oslo, Norway, 15 December 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has entered into a collaboration agreement with T... |
| 13.12.2022 | Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH |
STOCKHOLM — December 12, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company presents n... |
| 09.12.2022 | Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTI... |
| 07.12.2022 | Oncopeptides provides update on Pepaxto US marketing authorization | STOCKHOLM — December 07, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Admin... |
| 05.12.2022 | Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis | Stockholm, December 5, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), today launched the pivotal phase of COMPANION, the first clinical investigation of a... |
| 01.12.2022 | Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema | Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life
REDWOOD CITY, Calif. & TOKYO–(BUSINESS WIRE)–Nov. 30, 2022– Pulmonx Corporation (... |
| 26.11.2022 | Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank | STOCKHOLM — November 25, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announced that the company has entered ... |
| 16.11.2022 | Priothera – Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy | Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell transplantation (HCT) patients
Mocravimod significantly reduced circulating lymphocyte numbers and did not affect engraftment
DUBLIN, Nov. 14, 2022 /PRNewswire/ — Prio... |
| 11.11.2022 | Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates | CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment
Appointment of Saba Sile, M.D., as Vice President of Clinical Development
SAN FRANCISCO–(BUSINESS WIRE)–Nov. 10, 2022– Spruce Biosciences, Inc. (Nasda... |
| 11.11.2022 | Oncopeptides’ Pepaxti has been granted marketing authorization in the UK | STOCKHOLM — November 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that Pepaxti® (melphalan fluf... |
| 10.11.2022 | Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations | BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) ... |
| 10.11.2022 | Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement | Oslo, Norway, 10 November 2022 – Targovax ASA (OSE: TRVX) and Hubro Therapeutics AS (Hubro) today announce that they have entered into an asset purchase agreement whereby Hubro acquires Targovax’s GM-CSF (Granulocyte macrophage colony-stimu... |
| 09.11.2022 | Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results And Clinical Program Updates | FPI-1434 Phase 1 data on track to be reported in first half of 2023
Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expressing FGFR3
Strong balance sheet with $205.5 million in cash, cash equivalents and investme... |
| 09.11.2022 | Oncopeptides announces the market potential for Pepaxti in Europe | STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces the estimated market potential... |
| 09.11.2022 | Oncopeptides publishes Q3 report 2022 | STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the third quart... |
| 04.11.2022 | Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21 | Stockholm, November 3, 2022 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), provides a new interim analysis of the ongoing AIR trial, a phase 2... |
| 04.11.2022 | Pulmonx Reports Third Quarter 2022 Financial Results | REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarte... |
